Research AI

Scans

Tools

Watchlists

Home

Charts

Watchlist

Products

JFL Life Sciences Ltd

JFLLIFE·NSE

₹9.95-4.78%Wed, 23 Sept '26

Industry:Pharma - Formulators

Indices:

JFL Life Sciences Ltd

JFLLIFE

NSE

₹9.95

-4.78%

|Wed, 23 Sept '26

SOICxStockScans Reports

Industry

Pharma - Formulators

Indices

View

Financials

Documents

Shareholdings

Corporate Actions

Segments

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Financials

Documents

Shareholdings

Corporate Actions

Segments

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Quick Ratios

Edit Ratios

Mkt Cap

Market Capitalization

₹33Cr

Close Price

₹9.95

Industry

Pharma - Formulators

Price To Earnings

5.00

Price To Sales

0.25

Revenue

₹131Cr

Rev Gr TTM

Revenue Growth TTM

55.69%

PAT Gr TTM

PAT Growth TTM

123.84%

Quarterly Results

Standalone

Numbers

Percentage

Quarter	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	22	10	40	21	12	12	30	27	63	11
Growth YoY Revenue Growth YoY%					-45.9	21.5	-24.3	26.3	437.5	-4.2
Expenses ExpensesCr	20	6	37	20	10	10	27	23	60	9
Operating Profit Operating ProfitCr	2	3	2	1	1	2	3	3	4	2
OPM OPM%	7.1	32.0	6.1	6.3	11.8	16.6	9.8	12.5	5.6	18.8
Other Income Other IncomeCr	0	0	0	0	0	0	0	0	0	0
Interest Expense Interest ExpenseCr	0	0	0	0	0	0	0	0	1	0
Depreciation DepreciationCr	0	0	0	0	0	0	0	0	0	0
PBT PBTCr	1	3	2	1	1	1	2	3	2	1
Tax TaxCr	0	1	0	0	1	1	0	1	1	0
PAT PATCr	1	2	1	1	0	1	2	2	2	1
Growth YoY PAT Growth YoY%					-93.3	-60.7	35.9	173.0	1,975.0	48.0
NPM NPM%	5.5	20.0	3.7	3.5	0.7	6.5	6.6	7.5	2.6	10.0
EPS EPS₹	0.1	0.6	1.3	0.2	0.0	0.2	0.6	0.6	0.5	0.3

Quarter	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	22	10	40	21	12	12	30	27	63	11
Growth YoY Revenue Growth YoY%					-45.9	21.5	-24.3	26.3	437.5	-4.2
Expenses ExpensesCr	20	6	37	20	10	10	27	23	60	9
Operating Profit Operating ProfitCr	2	3	2	1	1	2	3	3	4	2
OPM OPM%	7.1	32.0	6.1	6.3	11.8	16.6	9.8	12.5	5.6	18.8
Other Income Other IncomeCr	0	0	0	0	0	0	0	0	0	0
Interest Expense Interest ExpenseCr	0	0	0	0	0	0	0	0	1	0
Depreciation DepreciationCr	0	0	0	0	0	0	0	0	0	0
PBT PBTCr	1	3	2	1	1	1	2	3	2	1
Tax TaxCr	0	1	0	0	1	1	0	1	1	0
PAT PATCr	1	2	1	1	0	1	2	2	2	1
Growth YoY PAT Growth YoY%					-93.3	-60.7	35.9	173.0	1,975.0	48.0
NPM NPM%	5.5	20.0	3.7	3.5	0.7	6.5	6.6	7.5	2.6	10.0
EPS EPS₹	0.1	0.6	1.3	0.2	0.0	0.2	0.6	0.6	0.5	0.3

Profit & Loss

Standalone

Numbers

Percentage

Financial Year	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	32	30	33	34	43	47	82	131	131
Growth Revenue Growth%		-5.1	8.6	2.5	27.5	8.7	76.3	60.1	55.7
Expenses ExpensesCr	30	28	31	28	39	42	74	120	119
Operating Profit Operating ProfitCr	1	2	2	5	4	5	8	12	12
OPM OPM%	4.2	6.2	6.6	16.0	9.2	9.8	10.0	8.9	9.1
Other Income Other IncomeCr	0	0	0	1	2	1	0		0
Interest Expense Interest ExpenseCr	1	1	1	2	1	1	1	2	2
Depreciation DepreciationCr	0	0	0	0	0	0	1	1	1
PBT PBTCr	0	1	1	4	4	4	6	9	9
Tax TaxCr	0	0	0	1	1	0	2	2	2
PAT PATCr	0	0	1	3	3	3	4	6	7
Growth PAT Growth%		19.1	50.4	418.4	0.0	17.4	26.0	53.9	123.8
NPM NPM%	0.9	1.2	1.6	8.4	6.6	7.1	5.1	4.9	5.2
EPS EPS₹	0.6	0.7	0.9	4.1	0.9	0.3	1.2	1.9	2.0

Financial Year	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	32	30	33	34	43	47	82	131	131
Growth Revenue Growth%		-5.1	8.6	2.5	27.5	8.7	76.3	60.1	55.7
Expenses ExpensesCr	30	28	31	28	39	42	74	120	119
Operating Profit Operating ProfitCr	1	2	2	5	4	5	8	12	12
OPM OPM%	4.2	6.2	6.6	16.0	9.2	9.8	10.0	8.9	9.1
Other Income Other IncomeCr	0	0	0	1	2	1	0		0
Interest Expense Interest ExpenseCr	1	1	1	2	1	1	1	2	2
Depreciation DepreciationCr	0	0	0	0	0	0	1	1	1
PBT PBTCr	0	1	1	4	4	4	6	9	9
Tax TaxCr	0	0	0	1	1	0	2	2	2
PAT PATCr	0	0	1	3	3	3	4	6	7
Growth PAT Growth%		19.1	50.4	418.4	0.0	17.4	26.0	53.9	123.8
NPM NPM%	0.9	1.2	1.6	8.4	6.6	7.1	5.1	4.9	5.2
EPS EPS₹	0.6	0.7	0.9	4.1	0.9	0.3	1.2	1.9	2.0

Balance Sheet

Standalone

Numbers

Percentage

Financial Year	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	0	0	1	8	11	11	33	33
Reserves ReservesCr	5	5	6	3	21	25	6	13
Current Liabilities Current LiabilitiesCr	8	18	14	28	15	21	32	53
Non Current Liabilities Non Current LiabilitiesCr	3	1	8	9	2	1	1	7
Total Liabilities Total LiabilitiesCr	16	24	29	48	49	57	72	106
Current Assets Current AssetsCr	14	18	20	39	41	44	60	92
Non Current Assets Non Current AssetsCr	3	6	9	9	8	13	12	15
Total Assets Total AssetsCr	16	24	29	48	49	57	72	106

Financial Year	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	0	0	1	8	11	11	33	33
Reserves ReservesCr	5	5	6	3	21	25	6	13
Current Liabilities Current LiabilitiesCr	8	18	14	28	15	21	32	53
Non Current Liabilities Non Current LiabilitiesCr	3	1	8	9	2	1	1	7
Total Liabilities Total LiabilitiesCr	16	24	29	48	49	57	72	106
Current Assets Current AssetsCr	14	18	20	39	41	44	60	92
Non Current Assets Non Current AssetsCr	3	6	9	9	8	13	12	15
Total Assets Total AssetsCr	16	24	29	48	49	57	72	106

Cash Flow

Standalone

Financial Year	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	-3	3	-6	2	-9	8	-4	-4
Investing Cash Flow Investing Cash FlowCr	-1	-3	-2	-1	1	-6	0	-4
Financing Cash Flow Financing Cash FlowCr	4	0	7	-1	8	-2	4	9
Net Cash Flow Net Cash FlowCr	0	0	0	0	0	0	0	1
Free Cash Flow Free Cash FlowCr	-4	0	-8	1	-9	2	-4
CFO To PAT CFO To PAT%	-992.2	891.5	-1,082.0	82.6	-322.7	253.2	-84.9	-67.7
CFO To EBITDA CFO To EBITDA%	-227.2	172.4	-271.3	43.3	-230.8	182.4	-43.1	-37.0

Financial Year	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	-3	3	-6	2	-9	8	-4	-4
Investing Cash Flow Investing Cash FlowCr	-1	-3	-2	-1	1	-6	0	-4
Financing Cash Flow Financing Cash FlowCr	4	0	7	-1	8	-2	4	9
Net Cash Flow Net Cash FlowCr	0	0	0	0	0	0	0	1
Free Cash Flow Free Cash FlowCr	-4	0	-8	1	-9	2	-4
CFO To PAT CFO To PAT%	-992.2	891.5	-1,082.0	82.6	-322.7	253.2	-84.9	-67.7
CFO To EBITDA CFO To EBITDA%	-227.2	172.4	-271.3	43.3	-230.8	182.4	-43.1	-37.0

Ratios

Standalone

Financial Year	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr					36	43	58	28	33
Price To Earnings Price To Earnings					12.9	13.1	13.8	4.4	5.0
Price To Sales Price To Sales					0.8	0.9	0.7	0.2	0.3
Price To Book Price To Book					1.1	1.2	1.5	0.6	0.7
EV To EBITDA EV To EBITDA					11.1	10.6	8.3	4.1	4.6
Profitability Ratios Profitability Ratios
GPM GPM%	7.6	11.1	11.1	22.3	18.3	13.2	18.8
OPM OPM%	4.2	6.2	6.6	16.0	9.2	9.8	10.0	8.9	9.1
NPM NPM%	0.9	1.2	1.6	8.4	6.6	7.1	5.1	4.9	5.2
ROCE ROCE%	8.7	12.7	9.7	21.7	13.0	11.3	14.4	15.8	15.8
ROE ROE%	6.0	6.7	7.9	24.9	8.7	9.3	10.5	13.9	13.9
ROA ROA%	1.9	1.5	1.9	5.8	5.7	5.8	5.8	6.0	6.0
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr					36	43	58	28	33
Price To Earnings Price To Earnings					12.9	13.1	13.8	4.4	5.0
Price To Sales Price To Sales					0.8	0.9	0.7	0.2	0.3
Price To Book Price To Book					1.1	1.2	1.5	0.6	0.7
EV To EBITDA EV To EBITDA					11.1	10.6	8.3	4.1	4.6
Profitability Ratios Profitability Ratios
GPM GPM%	7.6	11.1	11.1	22.3	18.3	13.2	18.8
OPM OPM%	4.2	6.2	6.6	16.0	9.2	9.8	10.0	8.9	9.1
NPM NPM%	0.9	1.2	1.6	8.4	6.6	7.1	5.1	4.9	5.2
ROCE ROCE%	8.7	12.7	9.7	21.7	13.0	11.3	14.4	15.8	15.8
ROE ROE%	6.0	6.7	7.9	24.9	8.7	9.3	10.5	13.9	13.9
ROA ROA%	1.9	1.5	1.9	5.8	5.7	5.8	5.8	6.0	6.0
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Documents — JFL Life Sciences Ltd

Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/tl2tw2jc47dld4lhot5x28gy.pdf
Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/9yvyo1i1z42384fob1gd238u.pdf
Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/pek04ker7c64t5bggc7ceoco.pdf
Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/0rbkd7v4o87bsfano4ia5lb9.pdf
Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/fm7ogud960bz1on4vw469ssa.pdf
Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/1re94cl33vbn8n2f3nbnxglr.pdf
Q4 FY2024 Quarterly Result (Mar 2024, PDF): https://www.stockscans.in/document/wa3ekmz3c2g4xktf85ib24ra.pdf
FY2026 Annual Report (PDF): https://www.stockscans.in/document/x80i4kgk1ywykqb9cskefhr8.pdf
FY2025 Annual Report (PDF): https://www.stockscans.in/document/jev408sap5jl5nzl4v1jxo8w.pdf
FY2024 Annual Report (PDF): https://www.stockscans.in/document/t6y1ovuxav12153k4jefalbc.pdf
FY2023 Annual Report (PDF): https://www.stockscans.in/document/t1vr0m41vzqkb660nxfsa3lk.pdf

Simplify stock analysis with powerful tools and clear insights for confident, data-driven decisions.

support@stockscans.in

349 A, Lodhi Road, Punjabi Bazar, New DelhiData provided by CMOTS Internet Technologies